

**Listing of Claims:**

1. (previously presented) A composition comprising an agent effective to elicit an immunogenic response to alpha-synuclein and an adjuvant that is pharmaceutically acceptable for human administration, wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF, wherein the agent is alpha-synuclein or an immunogenic fragment thereof.
2. (canceled)
3. (currently amended) The composition of claim 1~~claim 2~~, wherein the agent is alpha-synuclein.
4. (currently amended) The composition of claim 1~~claim 2~~, wherein the agent is immunogenic alpha-synuclein fragment.
5. (previously presented) The composition of claim 4, wherein the agent is NAC.
6. (currently amended) The composition of any one of claims 1 or 3 - 5 ~~claims 1-5~~, wherein the agent is linked to a carrier molecule to form a conjugate.
- 7-8. (canceled)
9. (previously presented) A composition comprising an agent effective to elicit an immunogenic response against an alpha-synuclein component of an amyloid plaque in a patient and an adjuvant that is pharmaceutically acceptable for human administration wherein the adjuvant is selected from the group consisting of QS21, monophosphoryl lipid, alum, CpG, GM-CSF and M-CSF.
10. (previously presented) The composition of claim 9, wherein the agent is alpha-synuclein or an immunogenic alpha-synuclein fragment.

11. (previously presented) The composition of claim 9, wherein the agent is alpha-synuclein.

12. (previously presented) The composition of claim 9, wherein the agent is an immunogenic alpha-synuclein fragment.

13. (previously presented) The composition of claim 12, wherein the immunogenic alpha-synuclein fragment is NAC.

14-53. (canceled)

54. (previously presented) The composition of claim 1, manufactured under good manufacturing practice conditions.

55. (previously presented) The composition of claim 1, wherein the agent is filter sterilized.